El Helali A et al (2022) A meta-analysis with systematic review: efficacy and safety of immune checkpoint inhibitors in patients with advanced gastric cancer. Front Oncol 12:908026

Article  PubMed Central  Google Scholar 

Hu X et al (2020) Immune checkpoint inhibitors and survival outcomes in brain metastasis: a time series-based meta-analysis. Front Oncol 10:564382

Article  PubMed  PubMed Central  Google Scholar 

Lamba N, Ott PA, Iorgulescu JB (2022) Use of first-line immune checkpoint inhibitors and association with overall survival among patients with metastatic melanoma in the anti-PD-1 era. JAMA Netw Open 5(8):e2225459

Article  PubMed Central  Google Scholar 

Youn B et al (2020) Real-world use and survival outcomes of immune checkpoint inhibitors in older adults with non-small cell lung cancer. Cancer 126(5):978–985

Article  CAS  PubMed  Google Scholar 

Zhu A et al (2023) Immune checkpoint inhibitors and long-term survival of patients with metastatic urothelial cancer. JAMA Netw Open 6(4):e237444

Article  PubMed Central  Google Scholar 

Michel L, Rassaf T, Totzeck M (2019) Cardiotoxicity from immune checkpoint inhibitors. Int J Cardiol Heart Vasc 25:100420

PubMed  PubMed Central  Google Scholar 

Larkin J et al (2019) Five-year survival with combined nivolumab and ipilimumab in advanced melanoma. N Engl J Med 381(16):1535–1546

Article  CAS  Google Scholar 

Robert C et al (2019) Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study. Lancet Oncol 20(9):1239–1251

Article  CAS  PubMed  Google Scholar 

Ferris RL et al (2016) Nivolumab for recurrent squamous-cell carcinoma of the head and neck. N Engl J Med 375(19):1856–1867

Article  PubMed  PubMed Central  Google Scholar 

Nghiem P et al (2021) Three-year survival, correlates and salvage therapies in patients receiving first-line pembrolizumab for advanced Merkel cell carcinoma. J Immunother Cancer 9(4):e002478

Article  PubMed  PubMed Central  Google Scholar 

Reck M et al (2016) Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. N Engl J Med 375(19):1823–1833

Article  CAS  PubMed  Google Scholar 

Schilsky RL et al (2020) Progress in cancer research, prevention, and care. N Engl J Med 383(10):897–900

Article  PubMed  Google Scholar 

Wei SC, Duffy CR, Allison JP (2018) Fundamental mechanisms of immune checkpoint blockade therapy. Cancer Discov 8(9):1069–1086

Article  PubMed  Google Scholar 

Gan L et al (2022) Cardiotoxicity associated with immune checkpoint inhibitors: current status and future challenges. Front Pharmacol 13:962596

Article  CAS  PubMed  PubMed Central  Google Scholar 

Li C, Bhatti SA, Ying J (2022) Immune checkpoint inhibitors-associated cardiotoxicity. Cancers (Basel) 14(5):1145

Article  CAS  PubMed  Google Scholar 

Michel L et al (2022) Targeting early stages of cardiotoxicity from anti-PD1 immune checkpoint inhibitor therapy. Eur Heart J 43(4):316–329

Article  CAS  PubMed  Google Scholar 

Lyon AR et al (2022) 2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS). Eur Heart J 43(41):4229–4361

Article  PubMed  Google Scholar 

Herrmann J et al (2022) Defining cardiovascular toxicities of cancer therapies: an International Cardio-Oncology Society (IC-OS) consensus statement. Eur Heart J 43(4):280–299

Article  PubMed  Google Scholar 

Battisti NML et al (2022) Prevalence of cardiovascular disease in patients with potentially curable malignancies: a national registry dataset analysis. JACC CardioOncol 4(2):238–253

Article  PubMed  PubMed Central  Google Scholar 

Yousif LI et al (2023) Risk factors for immune checkpoint inhibitor-mediated cardiovascular toxicities. Curr Oncol Rep 25(7):753–763

Article  PubMed Central  Google Scholar 

Ferdinandy P et al (2019) Definition of hidden drug cardiotoxicity: paradigm change in cardiac safety testing and its clinical implications. Eur Heart J 40(22):1771–1777

Article  CAS  PubMed  Google Scholar 

Michel L, Rassaf T, Totzeck M (2018) Biomarkers for the detection of apparent and subclinical cancer therapy-related cardiotoxicity. J Thorac Dis 10(Suppl 35):S4282–S4295

Article  PubMed  PubMed Central  Google Scholar 

Blake GJ, Ridker PM (2002) Inflammatory bio-markers and cardiovascular risk prediction. J Intern Med 252(4):283–294

Article  CAS  PubMed  Google Scholar 

Ravindranathan D, Master VA, Bilen MA (2021) Inflammatory markers in cancer immunotherapy. Biology (Basel) 10(4):325

CAS  Google Scholar 

Zhan L et al (2021) Predictive value of neutrophil/lymphocyte ratio (NLR) on cardiovascular events in patients with COVID-19. Int J Gen Med 14:3899–3907

Article  PubMed Central  Google Scholar 

Higaki A et al (2022) Predictive value of neutrophil-to-lymphocyte ratio for the fatality of COVID-19 patients complicated with cardiovascular diseases and/or risk factors. Sci Rep 12(1):13606

Article  CAS  PubMed  PubMed Central  Google Scholar 

Bhat T et al (2013) Neutrophil to lymphocyte ratio and cardiovascular diseases: a review. Expert Rev Cardiovasc Ther 11(1):55–59

Article  CAS  Google Scholar 

Qiao S, Gao W, Guo S (2020) Neutrophil-lymphocyte ratio (NLR) for predicting clinical outcomes in patients with coronary artery disease and type 2 diabetes mellitus: a propensity score matching analysis. Ther Clin Risk Manag 16:437–443

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kaya MG et al (2013) Prognostic value of neutrophil/lymphocyte ratio in patients with ST-elevated myocardial infarction undergoing primary coronary intervention: a prospective, multicenter study. Int J Cardiol 168(2):1154–1159

Article  PubMed  Google Scholar 

Cho JH et al (2020) Neutrophil-lymphocyte ratio in patients with acute heart failure predicts in-hospital and long-term mortality. J Clin Med 9(2):557

Article  CAS  PubMed  PubMed Central  Google Scholar 

Akinci Ozyurek B et al (2017) Prognostic value of the neutrophil to lymphocyte ratio (NLR) in lung cancer cases. Asian Pac J Cancer Prev 18(5):1417–1421

PubMed  Google Scholar 

Liang L et al (2023) Inflammatory biomarkers in assessing severity and prognosis of immune checkpoint inhibitor-associated cardiotoxicity. ESC Heart Fail 10(3):1907–1918

Article  PubMed Central  Google Scholar 

Baruch R et al (2023) High neutrophil-to-lymphocyte ratio as an early sign of cardiotoxicity in breast cancer patients treated with anthracycline. Clin Cardiol 46(3):328–335

Article  PubMed Central  Google Scholar 

Drobni ZD et al (2020) Decreased absolute lymphocyte count and increased neutrophil/lymphocyte ratio with immune checkpoint inhibitor-associated myocarditis. J Am Heart Assoc 9(23):e018306

Article  CAS  PubMed  PubMed Central  Google Scholar 

Chen X et al (2022) Immune checkpoint inhibitor-associated cardiotoxicity in solid tumors: real-world incidence, risk factors, and prognostic analysis. Front Cardiovasc Med 9:882167

Article  CAS  PubMed  PubMed Central  Google Scholar 

D’Souza M et al (2021) The risk of cardiac events in patients receiving immune checkpoint inhibitors: a nationwide Danish study. Eur Heart J 42(16):1621–1631

Article  PubMed  Google Scholar 

Ganatra S, Neilan TG (2018) Immune checkpoint inhibitor-associated myocarditis. Oncologist 23(8):879–886

Article  PubMed  PubMed Central  Google Scholar 

Mahmood SS et al (2018) Myocarditis in patients treated with immune checkpoint inhibitors. J Am Coll Cardiol 71(16):1755–1764

Article  CAS  PubMed  PubMed Central  Google Scholar 

He S et al (2021) Correlation between neutrophil to lymphocyte ratio and myocardial injury in population exposed to high altitude. Front Cardiovasc Med 8:738817

Article  CAS  PubMed  PubMed Central  Google Scholar 

Gurdal A et al (2020) Prognostic value of the neutrophil-to-lymphocyte ratio in patients with myocardial infarction with non-obstructive coronary arteries. Angiology 71(9):812–816

Article